The medium of instruction for classroom teaching (in all forms) at HKBU is English, except for those courses that are granted exemption.
HK$42,100 (local); HK$145,000 (non-local) i
The programme encompasses pharmaceutical science of Chinese Materia Medica (CMM), basic theories of Chinese medicine, basic science, western pharmacy and practicum training. During the four-year study, students are required to complete a 15-week practicum and an Honours Project. Throughout the programme, research concepts and tools are introduced, and the concept of "Whole Person Education" is also emphasized in the student-oriented General Education programme.
Student Learning Experiences
Starting from year one of the study, student will attend the practicum sessions in which they have plenty opportunities to broaden their knowledge. In the second year, students are required attend a 2-week practicum in the Medicinal Botany. During the summer breaks after the third and fourth years of study, they will attend the practicum in either a pharmaceutical plant or an herbarium in Hong Kong, Shenzhen or Guangzhou.
Career opportunities of the BPharm graduate include CMM quality control in the government and business management in the commercial sector of Chinese medicines. Graduates can also pursue research postgraduate study in either local or overseas institutions for th development of new drugs.
Programme Entrance Requirements
Applicants applying to the programme are expected to have taken Chemistry and possess a Chinese language qualification as deemed acceptable by the University.
For applicants holding international qualifications, they may fulfill the Chinese Language requirement with the following Chinese qualifications:
|Proficiency Tests||Minimum Requirements|
|GCE A/ AS Level Chinese||Grade E|
|GCSE/ IGCSE/ GCE O-Level Chinese/ Chinese Language||Grade C/ Grade 4|
|HKDSE Applied Learning Chinese||Attained|
|Others||Other Chinese language qualifications deemed acceptable by the University|
For international applicants (non-local non-mainland applicants), School of Chinese Medicine will not consider second choice applicants in admissions for 2024 entry.